

GENENT.065A



PATENT

#1218
MB
05/10/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : DeSavage et al.

Appl. No. : 09/272,835

Filed : March 19, 1999

For : GRF α 3 AND ITS USES


Examiner : Robert Hayes

) Group Art Unit 1647

) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as first-class
) mail in an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

) April 27, 2001

) (Date)

) 
) Ginger R. Dreger, Reg. No. 33,055

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed on October 27, 2000 (Paper No. 20), please amend this application as follows:

In the Specification:

Please replace the paragraph beginning at page 1, line 11, with the following rewritten paragraph:

--Neurotrophic factors such as insulin-like growth factors, nerve growth factors, brain-derived neurotrophic factor, neurotrophin-3, -4/5 and -6, ciliary neurotrophic factor, GDNF, and neurturin have been proposed as potential means for enhancing specific neuronal cell survival, for example, as a treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, stroke, epilepsy, Huntington's disease, Parkinson's disease, and peripheral neuropathy. It would be desirable to provide additional therapy for this purpose. Protein neurotrophic factors, or neurotrophins, which influence growth and development of the vertebrate system, are believed to play an important role in promoting the differentiation, survival, and function of diverse groups of neurons in the brain and periphery. Neurotrophic